Forward Looking Statements
|
|
- Moses Hunt
- 7 years ago
- Views:
Transcription
1 JUNE 2016 [ 1 ]
2 Forward Looking Statements SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS In addition to historical information, this presentation contains forward-looking statements with respect to our business, capital resources, strategic initiatives and growth reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including regarding continuing adoption of, and interest in, Senza in the U.S. and international markets; our beliefs regarding market size and share for Senza; our beliefs regarding the advantages of Senza and HF10 therapy; our expectations regarding our commercialization efforts, including sales force expansion and the launch of our surgical lead; and our expectations for worldwide revenue for the full year These forward-looking statements are based upon information that is currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; our ability to manufacture our products to meet demand; the level and availability of third-party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K filed on February 29, 2016 and our Quarterly Report on Form 10-Q filed on May 9, 2016, as well as any reports that we may file with the Securities and Exchange Commission in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. [ 2 ]
3 Nevro: A Leader in Neuromodulation DIFFERENTIATED Technology Superior to Traditional SCS and Protected by 100+ Patents ATTRACTIVE Market Growing $1.7B Market, Existing Reimbursement, Potential to Take Share and Grow Existing Market FIRST in Class Evidence First Pivotal RCT with Comparative Effectiveness Data, All Primary and Secondary Endpoints Met DEMONSTRATED Execution Commercial Success in United States, Europe and Australia PLATFORM Potential Market Expansion by Treating Back Pain and Other Indication Expansion Opportunities 7,000+ Patients in 17 MARKETS Over 5 YEARS [ 3 ]
4 Recent Highlights FDA Approval & Superiority Labeling for HF10 Therapy 12-Month Publication in Anesthesiology 12 Month SENZA-RCT Results published in Anesthesiology (titled Novel 10 KHz High Frequency Therapy (HF10 Therapy) Is Superior to Traditional Low Frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: The SENZA-RCT Randomized Controlled Trial ) IPR Patent Challenge Victory U.S. Patent and Trademark Office denied Boston Scientific Petitions for Inter Partes Review of U.S. Patent No. 8,359,102 CMS Approval of Transitional Pass-Through Payment Centers for Medicare & Medicaid Services (CMS) Approves a Transitional Pass-Through Payment for High Frequency Stimulation under the Medicare Hospital Outpatient Prospective Payment System Effective Beginning January 1, 2016 Consistent International Performance ~70% YoY growth in 1Q15, ~80% growth in 2Q15, ~50% growth in 3Q15, ~55% growth in 4Q15, and ~30% growth in 1Q16 on a constant currency basis Successful US Launch Growing number of clinics across the U.S. are continuing to adopt HF10 therapy and outcomes in commercial use are consistent with clinical outcomes from SENZA-RCT FDA Approval for New Surgical Leads for the Senza SCS System [ 4 ]
5 Delivering on the Promise of HF10 Therapy FY15 Revenue: $69.6M U.S. Reps Trained & In Field $ in Millions International Revenue U.S. Revenue $ $33.1 $12.2 At Launch 5/8/15 2Q15 3Q15 4Q15 1Q16 $13.3 $15.4 $9.7 $11.4 $29.5 $10.9 $19.8 $9.7 $11.3 $0.1 $4.5 1Q15 2Q15 3Q15 4Q15 1Q16 Penetrating AND Growing the SCS Market Predom. Back Predom. Leg Back & Leg Other Pain Distribution of HF10 Treated Patients U.S. Launch through Jan 1, 2016 ~50% ~5% ~30% ~15% [ 5 ]
Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation
Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Hans S. Keirstead President, NeoStem Oncology NeoStem Presented by GTC, a conference production company 626-256-6405
More informationXENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14
XENOPORT INC FORM 8-K (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 Address 3410 CENTRAL EXPRESSWAY SANTA CLARA, CA 95051 Telephone 4086167200 CIK 0001130591 Symbol XNPT SIC Code
More informationFORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011
More informationA LEADING GLOBAL HEALTH CARE GROUP. Frankfurt Stock Exchange (DAX30): FRE US ADR program (OTC): FSNUY wwww.fresenius.com/investors
A LEADING GLOBAL HEALTH CARE GROUP Frankfurt Stock Exchange (DAX30): FRE US ADR program (OTC): FSNUY wwww.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains forward-looking statements
More informationStifel Technology, Media and Internet Conference. February 2015
Stifel Technology, Media and Internet Conference February 2015 Safe Harbor This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management s
More informationALPHA TEST LICENSE AGREEMENT
ALPHA TEST LICENSE AGREEMENT IMPORTANT NOTICE! PLEASE READ THIS STATEMENT AND THE ALPHA TEST LICENSE AGREEMENT COMPLETELY BEFORE USING THIS ALPHA SOFTWARE. BY CLICKING ON THE BUTTON MARKED YES BELOW OR
More informationHMS Announces Definitive Agreement To Acquire HDI
HMS Announces Definitive Agreement To Acquire HDI November 7, 2011 Bill Lucia, President and CEO Walter Hosp, SVP and CFO Contact: Christine Saenz csaenz@hms.com 212.857.5986 Safe Harbor Statemente t This
More informationInnovative Technology Solutions for Sustainability ABENGOA. H1 2015 Preliminary Results
Innovative Technology Solutions for Sustainability ABENGOA H1 2015 Preliminary Results July 23, 2015 Financial Information Disclaimer The consolidated financial data for the first half of 2015 ended June
More informationEpimed Would Like To Congratulate The 20th Annual Budapest Conference The New Shape of Pain Relief SmalleST. ThiNNeST. CoNTouRed design. Precision Novi is the world s smallest, thinnest 16 contact primary
More informationPain Therapeutics, Inc.
Pain Therapeutics, Inc. Pioneers in Preventing Prescription Drug Abuse Remi Barbier President & CEO June 2014 1 Forward-Looking Statements This presentation contains forward-looking statements within the
More informationNETWORK-1 REPORTS FIRST QUARTER 2013 RESULTS
FOR IMMEDIATE RELEASE Corey M. Horowitz, Chairman and CEO Network-1 Security Solutions, Inc. (212) 829-5770 NETWORK-1 REPORTS FIRST QUARTER 2013 RESULTS New York, New York May 15, 2013. Network-1 Security
More information1.5 Tesla and 3 Tesla Magnetic Resonance Imaging (MRI) Guidelines for the Senza System
1.5 Tesla and 3 Tesla Magnetic Resonance Imaging (MRI) Guidelines for the Senza System NEVRO CORP. All questions or concerns about Nevro products should be forwarded to: Nevro Corp. 1800 Bridge Parkway
More informationHow To Use Merrimack Web Site
TERMS AND CONDITIONS OF USE PLEASE READ THESE TERMS AND CONDITIONS OF USE CAREFULLY. THESE TERMS AND CONDITIONS OF USE MAY HAVE CHANGED SINCE YOUR LAST VISIT TO THIS WEB SITE. BY USING THIS WEB SITE, YOU
More informationA LEADING GLOBAL HEALTHCARE COMPANY
A LEADING GLOBAL HEALTHCARE COMPANY Roadshow Boston March 2, 2016 Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains
More informationCorporate Overview. April 2014 OTCQB: LCDX
Corporate Overview April 2014 OTCQB: LCDX Company Snapshot biopsy Provides non-invasive, point-of-care cellular imaging technologies VivaScope systems can improve patient outcomes while reducing costs
More informationReporting of Devices and Leads When a Credit is Received
Reporting of Devices and Leads When a Credit is Received Cardiac Rhythm Management and Electrophysiology Updated January 2014 Medicare Reporting Requirements For Full or Partial Credits of Devices and
More informationROFIN-SINAR REPORTS RESULTS FOR THE FIRST QUARTER OF FISCAL YEAR 2016
- PRESS RELEASE - Contact: Katharina Manok ROFIN-SINAR 011-49-40-733-63-4256 - or - 734-416-0206 ROFIN-SINAR REPORTS RESULTS FOR THE FIRST QUARTER OF FISCAL YEAR 2016 Quarterly earnings per share increased
More informationMedical Billing - The Government's Big Hammer
1 Becton Drive Franklin Lakes, NJ 07417 www.bd.com News Release Contact: Monique N. Dolecki, Investor Relations 201-847-5453 Alyssa J. Zeff, Corporate Communications 201-847-4358 BD ANNOUNCES RESULTS FOR
More informationReimbursement for Medical Products: Ensuring Marketplace
Reimbursement for Medical Products: Ensuring Marketplace Success by Securing Coverage and Payment Christopher J. Panarites, Ph.D. Director, Endovascular Products Health Economics and Outcomes Research
More informationU.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc.
U.S. Scientific Update Aricept 23 mg Tablets Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. Unmet Need in Moderate to Severe Alzheimer s Disease (AD) Ongoing clinical deterioration
More informationSpinal Cord Stimulation (SCS) Therapy: Fact Sheet
Spinal Cord Stimulation (SCS) Therapy: Fact Sheet What is SCS Therapy? Spinal cord stimulation (SCS) may be a life-changing 1 surgical option for patients to control their chronic neuropathic pain and
More informationZebra Technologies Announces Record Sales for Second Quarter of 2006
FOR IMMEDIATE RELEASE Zebra Technologies Announces Record Sales for Second Quarter of 2006 Vernon Hills, IL, July 26, 2006 Zebra Technologies Corporation (NASDAQ: ZBRA) today announced that net income
More informationRotator Cuff Repair Surgical Procedures
Rotator Cuff Repair Surgical Procedures 2011 Reimbursement and Coding Reference Guide for Physicians and Hospitals This coding reference guide is intended to illustrate the common CPT * codes, ICD-9 CM
More informationSORRENTO THERAPEUTICS, INC.
ˆ200F@WVSVmdG1Yng+Š 200F@WVSVmdG1Yng+ AZ0151AC599817 11.3.10 SWRvelaj0nb 31-Jul-2013 16:51 EST 577580 TX 1 3* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant
More informationThe Future of Consumer Health Care
The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry 2 Creating a New Business Model in Consumer Health Care 3 Serve More Consumers In More Parts of the World, More
More informationHealth Care Worldwide
Health Care Worldwide Goldman Sachs - Leveraged Finance Healthcare Conference March 4, 2014 New York Goldman Sachs Leveraged Finance Conference, Fresenius SE & Co. KGaA Copyright, March 4, 2014 Page 1
More informationKYPHON. Reimbursement Guide. Physician Reimbursement. Balloon Kyphoplasty Procedure. ICD-9-CM Diagnosis Codes. CPT Codes and Payment
KYPHON Balloon Kyphoplasty Procedure Reimbursement Guide ICD-9-CM Diagnosis Codes Providers should report the ICD-9-CM diagnosis code that most accurately describes the patient s condition. Please refer
More informationHow to Develop a Clinical Study Site Budget
How to Develop a Clinical Study Site Budget Mary Fautsch Dale Klous White Paper 6/23/2011 Abstract Summary In today s dynamic environment, there is a need like never before for clinical data. In addition
More informationRepligen Reports Third Quarter 2015 Financial Results
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2015 Financial Results - Product Sales Increase 31% to $19.8 Million - - Conference
More informationPlanning for Successful Medical Device Reimbursement:
Planning for Successful Medical Device Reimbursement: So Your Device Is Cleared, By Tiffini Diage, MPH Health Economics NAMSA White Paper Key Considerations for Targeting Success of Medical Device Sales
More informationTax Implications of the Covidien Acquisition to Medtronic Employees
To: All Medtronic Employees Date: Friday, June 27, 2014 Tax Implications of the Covidien Acquisition to Medtronic Employees Dear Colleagues, On June 15, 2014, Medtronic and Covidien publicly announced
More informationA World Leading Addiction Treatment Company with enormous future potential. JP Morgan Conference, San Francisco January 2016
A World Leading Addiction Treatment Company with enormous future potential JP Morgan Conference, San Francisco January 2016 Forward Looking Statements This presentation contains certain statements that
More informationVivint Wireless Internet Update. September 23, 2015
Vivint Wireless Internet Update September 23, 2015 preliminary statement This presentation includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995 including
More informationBank of America Merrill Lynch Leveraged Finance Conference. Robin Grey SVP, Treasurer. December 1, 2011
Bank of America Merrill Lynch Leveraged Finance Conference Robin Grey SVP, Treasurer December 1, 2011 Safe Harbor Statement Some of the statements made in this presentation are forward looking in nature.
More informationAir Methods Corporation NASDAQ: AIRM. Corporate Presentation November 2015
Air Methods Corporation NASDAQ: AIRM Corporate Presentation November 2015 Forward Looking Statements/ Non-GAAP Financial Information Forward Looking Statements: Forward-looking statements in this news
More informationTrademarkAuthority Legal Services Engagement Agreement
TrademarkAuthority Legal Services Engagement Agreement 1. THE PARTIES / EFFECTIVE DATE. This TrademarkAuthority Legal Services Engagement Agreement ( Agreement ) is made between ( Pearl Cohen ), the exclusive
More informationFORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September
More informationMEDICAL CONTESTED CASE HEARING NO 12090 M6-12-38043-01 DECISION AND ORDER
MEDICAL CONTESTED CASE HEARING NO 12090 M6-12-38043-01 DECISION AND ORDER This case is decided pursuant to Chapter 410 of the Texas Workers Compensation Act and Rules of the Division of Workers Compensation
More informationOhr Pharmaceutical Reports Fiscal Year 2015 Financial and Business Results
December 10, 2015 Ohr Pharmaceutical Reports Fiscal Year 2015 Financial and Business Results OHR-102 Phase 3 Program in Wet-AMD to be Initiated Upon Completion of SPA; Enroll Patients in Q1 2016 Conference
More informationAMERICAN INSTITUTES FOR RESEARCH OPEN SOURCE SOFTWARE LICENSE
AMERICAN INSTITUTES FOR RESEARCH OPEN SOURCE SOFTWARE LICENSE 1. DEFINITIONS. 1.1. "Contributor" means each individual or entity that creates or contributes to the creation of Modifications. 1.2. "Contributor
More informationTO CLOSE AND BEYOND CONNECTION THE VALUE CHAIN FROM MICHAEL KANE. Analyst and Investor Day 2014 May 22, 2014 SENIOR VICE PRESIDENT SOFTWARE BUSINESS
THE VALUE CHAIN FROM CONNECTION TO CLOSE AND BEYOND MICHAEL KANE SENIOR VICE PRESIDENT SOFTWARE BUSINESS Analyst and Investor Day 2014 May 22, 2014 Statements made in this presentation or orally accompanying
More informationTN0023 Technical note
Technical note Discontinuous flyback transformer description and design parameters Introduction The following is a general description and basic design procedure for a discontinuous flyback transformer.
More informationThird Quarter 2015 Financial Highlights:
DISCOVERY COMMUNICATIONS REPORTS THIRD QUARTER 2015 RESULTS, INCREASES BUYBACK AUTHORIZATION BY $2 BILLION AND ANNOUNCES RESUMPTION OF SHARE REPURCHASES BEGINNING IN FOURTH QUARTER 2015 Third Quarter 2015
More informationDeveloping Innovative Therapeutics for People with Orphan Liver Disease
Developing Innovative Therapeutics for People with Orphan Liver Disease PIPELINE PROGRESS AND FIRST QUARTER 2015 EARNINGS UPDATE NASDAQ: OCRX Forward-Looking Statements Certain statements in this presentation
More informationAn introduction to Optos
An introduction to Optos Building The Retina Company Roy Davis, CEO Christine Soden, CFO 1 Forward-Looking Statements Certain statements made in this presentation are forward-looking statements. These
More informationDERMABOND Portfolio 2012 LACERATION REPAIR REIMBURSEMENT GUIDE
2012 LACERATION REPAIR REIMBURSEMENT GUIDE ETHICON, INC. IS PLEASED TO PROVIDE THIS LACERATION REPAIR REIMBURSEMENT GUIDE AS A RESOURCE FOR HEALTHCARE PROVIDERS. This guide is intended for informational
More informationTeva and Checkpoint Therapeutics Announce License Agreement for Oral PARP Inhibitor
Teva and Checkpoint Therapeutics Announce License Agreement f Oral PARP Inhibit Checkpoint to Obtain Exclusive Wldwide Development and Commercialization Rights Jerusalem and New Yk, NY, January 7, 2016
More informationA Phase 2 Study of HTX-011 in the Management of Post-Operative Pain Positive Top-Line Results
A Phase 2 Study of HTX-011 in the Management of Post-Operative Pain Positive Top-Line Results September 22, 2015 Forward-Looking Statements This presentation contains "forward-looking statements" as defined
More informationAir Methods Corporation NASDAQ: AIRM. Corporate Presentation December 2015
Air Methods Corporation NASDAQ: AIRM Corporate Presentation December 2015 Forward Looking Statements/ Non-GAAP Financial Information Forward Looking Statements: Forward-looking statements in this news
More informationIMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282
IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris
More informationPublic Patent & Trademarks - Drafting a Corporate Enforceableclosure Schedule
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationEmbedded Analytics. The new battleground of banking. Stuart Ward Director Financial Services, APAC, Qlik
Embedded Analytics The new battleground of banking Stuart Ward Director Financial Services, APAC, Qlik Legal Disclaimer This Presentation contains forward-looking statements, including, but not limited
More informationHitachi Transfers Hard Disk Drive Business to Western Digital
FOR IMMEDIATE RELEASE Hitachi Transfers Hard Disk Drive Business to Western Digital Irvine, Calif., U.S., and Tokyo, Japan, March 7, 2011 --- Western Digital Corporation (NYSE: WDC, WD ) and Hitachi, Ltd.
More informationEDWARDS LIFESCIENCES REPORTS STRONG FIRST QUARTER RESULTS DRIVEN BY SALES GROWTH OF 18.8 PERCENT
Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amanda C. Fowler, 949-250-5070 Investor
More informationUser Agreement. Quality. Value. Efficiency.
User Agreement Quality. Value. Efficiency. Welcome to QVuE, the Leaders Network on Quality, Value and Efficiency website sponsored by The Medicines Company. The information provided in this Webinar Series
More informationCODING SHEETS CHRONIC INTRACTABLE SPASTICITY. Effective January 1, 2009 CODMAN 3000 NEUROMODULATION AND ONCOLOGY REIMBURSEMENT HOTLINE
CODING SHEETS CHRONIC INTRACTABLE SPASTICITY Effective January 1, 2009 CODMAN 3000 NEUROMODULATION AND ONCOLOGY REIMBURSEMENT HOTLINE Phone: 800-609-1108 Email: codmanpump@aol.com Fax: 303-703-1572 CODMAN
More informationWeb Terms & Conditions
PART 1: OUR AGREEMENT WITH YOU 1. AGREEMENT 1.1 Parties This Agreement is made between Cheap Web Designers (ACN 126 117 619) of Suite 504, 365 Little Collins Street Melbourne VIC 3000 ("CWD") and YOU the
More informationPURCHASE ORDER TERMS AND CONDITIONS
PURCHASE ORDER TERMS AND CONDITIONS This purchase order is subject to the following terms and conditions. The terms and conditions herein set forth constitute an offer by Purchaser and may be accepted
More informationGreenway Marketplace. Matt Pierce Director of Partner Services. Kaitlin Samples National Partner Manager
Greenway Marketplace Matt Pierce Director of Partner Services Kaitlin Samples National Partner Manager Safe Harbor Safe harbor statement under the Private Securities Litigation Reform Act of 1995: This
More informationFlamel Technologies Announces Second Quarter Results of Fiscal Year 2015
Flamel Technologies Announces Second Quarter Results of Fiscal Year 2015 Product revenue guidance for 2015 of $170-$185 million reaffirmed Conference call with management to take place at 10:00 am ET on
More informationChapter 17. Medicaid Provider Manual
Chapter 17 Medicaid Provider Manual February 2011 TABLE OF CONTENTS 17.1 Occupational Therapy... 1 17.1.1 Description... 1 17.1.2 Amount, Duration and Scope... 1 17.1.3 Exclusions... 1 17.1.4 Limitations...
More informationUbiquitous secure file sharing on any device
Ubiquitous secure file sharing on any device This presentation is not an offer to sell or a solicitation of an offer to purchase securities by Zyber Secure Mobile Solutions Inc. ( Zyber ). Any such offer
More informationBNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
More informationCIGNA CORPORATION INVESTOR PRESENTATION. November 6, 2015. 2015 Cigna
CIGNA CORPORATION INVESTOR PRESENTATION November 6, 2015 1 Forward looking statements and non-gaap measures CAUTIONARY STATEMENT FOR PURPOSES OF THE SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION
More informationIntercontinentalExchange. Credit Suisse Financial Services Forum February 7, 2008
IntercontinentalExchange Credit Suisse Financial Services Forum February 7, 2008 Forward-Looking Statements Forward-Looking Statements This presentation may contain forward-looking statements made pursuant
More information2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative
Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life
More informationContractor Number 11302. Oversight Region Region IV
Local Coverage Determination (LCD): Spinal Cord Stimulators for Chronic Pain (L32549) Contractor Information Contractor Name Palmetto GBA opens in new window Contractor Number 11302 Contractor Type MAC
More informationAGM Presentation 27 November 2015
AGM Presentation 27 November 2015 Agenda Overview Segments Services Consumer Lending Business Lending Financial results 2015 5 Year Strategic Plan 2016 to 2020 July to October 2015 2 Overview Overview
More informationWestern Union. Khalid Fellahi, SVP & GM WU Digital. March 25, 2014
Western Union Khalid Fellahi, SVP & GM WU Digital March 25, 2014 SAFE HARBOR This presentation contains certain statements that are forward-looking within the meaning of the Private Securities Litigation
More informationCODING SHEETS CHRONIC INTRACTABLE PAIN MANAGEMENT. Effective January 1, 2011 CODMAN 3000 NEUROMODULATION AND ONCOLOGY REIMBURSEMENT HOTLINE
CODING SHEETS CHRONIC INTRACTABLE PAIN MANAGEMENT Effective January 1, 2011 CODMAN 3000 NEUROMODULATION AND ONCOLOGY REIMBURSEMENT HOTLINE Phone: 800-609-1108 Email: codmanpump@aol.com Fax: 303-703-1572
More informationCorporate Presentation May 13, 2015
Corporate Presentation May 13, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events and
More informationN E W S R E L E A S E
N E W S R E L E A S E Investors: Brett Manderfeld John Penshorn Media: Don Nathan Tyler Mason Vice President Senior Vice President Senior Vice President Vice President 952-936-7216 952-936-7214 952-936-1885
More informationFirst Quarter Fiscal 2010 Results Presentation
First Quarter Fiscal 2010 Results Presentation March 2, 2010 Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the safe harbor provisions of the
More informationLocalised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment
Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The
More informationASX Announcement. Presentation by David Griffith to Morgans Conference
ASX Announcement 21 October 2015 Presentation by David Griffith to Morgans Conference Attached is a presentation to be given later today by IPH s Managing Director, David Griffith to the Morgans Annual
More informationZapping the Pain Away: Technology and Pain Management www.neurotechnetwork.org. Jennifer French, MBA Executive Director Neurotech Network
Jennifer French, MBA Executive Director Neurotech Network Want to Ask a Question? Objectives Understanding the Pain Options for pain management Technology integration Resource to learn more Disclaimer
More informationA Leading Global Health Care Group
A Leading Global Health Care Group Commerzbank German Investment Seminar January 11/12, 2016 For detailed financial information please see our annual/quarterly reports and/or conference call materials
More informationHealth Care Worldwide
Health Care Worldwide Credit Suisse Global Credit Products Conference September 18, 2014 Miami Credit Suisse Global Credit Products Conference, September 18, 2014 Copyright Page 1 Safe Harbor Statement
More informationAmbulatory Surgery Center Coding and Payment Guide 2015
Targeted Drug Delivery Ambulatory Surgery Center Coding and Payment Guide 2015 Flowonix Medical has compiled this coding information for your convenience. This information is gathered from third party
More informationRUSSELL ON ICE 2016 LIQUIDITY ENHANCEMENT PROGRAMS
RUSSELL ON ICE 2016 LIQUIDITY ENHANCEMENT PROGRAMS JANUARY 2016 SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 DISCLAIMERS AND CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
More informationExpanded Frequency Capping
IMPLEMENTATION GUIDE Expanded Frequency Capping Ad Management at its best! August 2007 For more information, please contact support@zedo.com Disclaimer This Implementation Guide is for informational purposes
More informationEconomic aspects of Spinal Cord Stimulation (SCS)
Economic aspects of Spinal Cord Stimulation (SCS) Burden of Chronic Pain Chronic pain affects one in five adults in Europe 1. Up to 10 per cent of chronic pain cases are neuropathic in origin. 2 Chronic
More informationAgenda. Operating highlights and key initiatives. Financial results Q&A. John Legere, President and CEO. Braxton Carter, CFO
T-Mobile US Disclaimer This presentation contains forward-looking statements within the meaning of the U.S. federal securities laws. For those statements, we claim the protection of the safe harbor for
More informationHong Kong Joint Venture Agreements
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness,
More informationCorporate Presentation. May 2013
Mindray Medical International Limited Corporate Presentation May 2013 Disclaimer This material contains "forward looking statements" within the meaning of the safe harbor provisions of the U. S. Private
More informationCoverage and Authorization Services is available to respond to your coding questions toll-free at 800-292-2903.
For Urinary Control Commonly Billed Codes October 2010 Medtronic provides this information for your convenience only. It is not intended as a recommendation regarding clinical practice. It is the responsibility
More informationFinancial Services CNH Industrial Capital. Oddone Incisa
CNH Industrial Capital Oddone Incisa Integrated and Diversified across Regions and Asset Classes by Region ($ billion) Managed Portfolio $26.9 billion (YE 2013) by Segment 13.3 1.1 8.2 49% 4% NAFTA 31%
More informationRegal Beloit Corporation Second Quarter 2014 Earnings Conference Call
Regal Beloit Corporation Second Quarter 2014 Earnings Conference Call July 30, 2014 Mark Gliebe Chairman and Chief Executive Officer Jon Schlemmer Chief Operating Officer Chuck Hinrichs Vice President
More informationConifer Health Solutions Tenet Investor Webinar
Conifer Health Solutions Tenet Investor Webinar May 16, 2012 Stephen Mooney President, Conifer Health Solutions 1 2012 Conifer Health Solutions, LLC. All Rights Reserved. Forward Looking Statements Certain
More informationMorgan Stanley Leveraged Finance Conference
Morgan Stanley Leveraged Finance Conference June 12, 2014 2014 Level 3 Communications, LLC. All Rights Reserved Cautionary Statement & Pro Forma Adjustment Some statements made in this presentation are
More informationMedical Devices. Driving Growth With Transformational Technology
Medical Devices Driving Growth With Transformational Technology Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation
More informationB8746: Investing in Medical Technologies Fall 2015 (B-Term); Monday 5:45pm 9:00pm
B8746: Investing in Medical Technologies Fall 2015 (B-Term); Monday 5:45pm 9:00pm Instructor: Office: Email: TA: Email: Efrem Kamen, Founder & Managing Member, Pura Vida Investments, LLC TBD ejk28@columbia.edu
More informationAccenture Reports Third-Quarter Fiscal 2015 Results. -- Revenues of $7.8 billion, up 0.4% in U.S. dollars and 10% in local currency --
Accenture Reports Third-Quarter Fiscal 2015 Results -- Revenues of $7.8 billion, up 0.4% in U.S. dollars and 10% in local currency -- -- EPS of $1.24 include a $0.06 non-cash pension settlement charge.
More informationN E W S R E L E A S E
N E W S R E L E A S E Investors: Brett Manderfeld John S. Penshorn Media: Don Nathan Tyler Mason Vice President Senior Vice President Senior Vice President Vice President 952-936-7216 952-936-7214 952-936-1885
More informationAIXTRON Investor Presentation. Fiscal Year 2014 Results (February 24, 2015)
AIXTRON Investor Presentation Fiscal Year 2014 Results (February 24, 2015) DISCLAIMER Forward-Looking Statements 2 This document may contain forward-looking statements regarding the business, results of
More informationSanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)
PRESS RELEASE Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL) Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases
More informationINTRODUCTION. The Workers Compensation Act provides in part as follows:
INTRODUCTION The Maryland Workers Compensation Commission (Commission) amended COMAR 14.09.03.01 (Guide of Medical and Surgical Fees) on February 12, 2004. AUTHORITY The Workers Compensation Act provides
More information2015 Indiana General Assembly
2015 Indiana General Assembly As of Tuesday: 454 Senate Bills 349 House Bills Budget Full funding of Medicaid forecast $19M - IU medical school campus in Evansville $8M Enhance awareness and provide prenatal
More informationAttunity Acquires Appfluent, a Leading Provider of Strategic Solutions that Optimize the Economics and Performance of Big Data Analytics and Hadoop
Attunity Acquires Appfluent, a Leading Provider of Strategic Solutions that Optimize the Economics and Performance of Big Data Analytics and Hadoop Appfluent s software provides unprecedented visibility
More information"Account" means the Account open with NFDA by the Firm for Website Construction Services and Website Hosting Services.
Terms and Conditions Agreement between the National Funeral Directors Association ( NFDA ) and the Firm ( Firm ), which by selecting the various options listed at the end of this Agreement, is selecting
More information